Programs and Projects

Prostate Cancer Clinical Trials - University of Wisconsin

Agent: Diindolylmethane (DIM)
Contact: Jason Gee, M.D.
DCP Program Director: Howard Parnes, M.D.

The purpose of this study is to evaluate the potential of DIM as a chemopreventive agent for prostate cancer. Men with a diagnosis of prostate cancer who are considering surgical removal of the prostate gland (prostatectomy) may be eligible to participate in this study. Those taking part in the study will receive either DIM or placebo for several weeks immediately before prostate surgery. The study is being conducted at the University of Wisconsin Comprehensive Cancer Center and several other study sites through the University of Wisconsin Clinical Trials Consortium. This study is now open to accrual.

[This is a phase 2 randomized double-blind placebo controlled trial of the selective COX 2 inhibitor (Celecoxib) administered for 4-6 weeks in the presurgical period prior to prostatectomy in men with localized prostate cancer. The primary endpoint is modulation of prostaglandins in prostatic epithelium (normal, HGPIN and cancer).]